Gian Luca Di Tanna1,2, Blake Angell3, Michael Urbich4, Peter Lindgren5,6, Thomas A Gaziano7, Gary Globe8, Björn Stollenwerk9. 1. University of New South Wales, Sydney, NSW, Australia. gditanna@georgeinstitute.org.au. 2. The George Institute for Global Health, Level 5, 1 King St, Newtown, NSW, 2042, Australia. gditanna@georgeinstitute.org.au. 3. The George Institute for Global Health, Level 5, 1 King St, Newtown, NSW, 2042, Australia. 4. Biogen International GmbH, Baar, Switzerland. 5. Karolinska Institutet, Stockholm, Sweden. 6. The Swedish Institute for Health Economics, Lund, Sweden. 7. Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 8. Cerevel Therapeutics, Cambridge, MA, USA. 9. Amgen (Europe) GmbH, Economic Modeling Center of Excellence, Rotkreuz, Switzerland.
Abstract
BACKGROUND: The rate of events such as recurrent heart failure (HF) hospitalization and death are known to dramatically increase directly after HF hospitalization. Furthermore, the number of HF hospitalizations is associated with irreversible long-term disease progression, which is in turn associated with increased event rates. However, cost-effectiveness models of HF treatments commonly fail to capture both the short- and long-term association between HF hospitalization and events. OBJECTIVE: The aim of this study was to provide a decision-analytic model that reflects the short- and long-term association between HF hospitalization and event rates. Furthermore, we assess the impact of omitting these associations. METHODS: We developed a life-time Markov cohort model to evaluate HF treatments, and modeled the short-term impact of HF hospitalization on event rates via a sequence of tunnel states, with transition probabilities following a parametric survival curve. The corresponding long-term impact was modeled via hazard ratios per HF hospitalization. We obtained baseline event rates and utilities from published literature. Subsequently, we assessed, for a hypothetical HF treatment, how omitting the modeled associations (through a simple two-state model) affects incremental quality-adjusted life-years (QALYs). RESULTS: We developed a model that incorporates both short- and long-term impacts of HF hospitalizations. Based on an assumed treatment effect of a 20% risk reduction for HF hospitalization (and associated reductions in all-cause mortality of 15%), omitting the short-term, the long-term, or both associations resulted in a 5%, 1%, and 22% decrease in QALYs gained, respectively. CONCLUSION: For both modeling components, i.e., the short- and long-term implications of HF hospitalization, the impact on incremental outcomes associated with treatment was substantial. Considering these aspects as proposed within this modeling approach better reflects the natural course of this progressive condition and will enhance the evaluation of future HF treatments.
BACKGROUND: The rate of events such as recurrent heart failure (HF) hospitalization and death are known to dramatically increase directly after HF hospitalization. Furthermore, the number of HF hospitalizations is associated with irreversible long-term disease progression, which is in turn associated with increased event rates. However, cost-effectiveness models of HF treatments commonly fail to capture both the short- and long-term association between HF hospitalization and events. OBJECTIVE: The aim of this study was to provide a decision-analytic model that reflects the short- and long-term association between HF hospitalization and event rates. Furthermore, we assess the impact of omitting these associations. METHODS: We developed a life-time Markov cohort model to evaluate HF treatments, and modeled the short-term impact of HF hospitalization on event rates via a sequence of tunnel states, with transition probabilities following a parametric survival curve. The corresponding long-term impact was modeled via hazard ratios per HF hospitalization. We obtained baseline event rates and utilities from published literature. Subsequently, we assessed, for a hypothetical HF treatment, how omitting the modeled associations (through a simple two-state model) affects incremental quality-adjusted life-years (QALYs). RESULTS: We developed a model that incorporates both short- and long-term impacts of HF hospitalizations. Based on an assumed treatment effect of a 20% risk reduction for HF hospitalization (and associated reductions in all-cause mortality of 15%), omitting the short-term, the long-term, or both associations resulted in a 5%, 1%, and 22% decrease in QALYs gained, respectively. CONCLUSION: For both modeling components, i.e., the short- and long-term implications of HF hospitalization, the impact on incremental outcomes associated with treatment was substantial. Considering these aspects as proposed within this modeling approach better reflects the natural course of this progressive condition and will enhance the evaluation of future HF treatments.
Authors: Daniel Levy; Satish Kenchaiah; Martin G Larson; Emelia J Benjamin; Michelle J Kupka; Kalon K L Ho; Joanne M Murabito; Ramachandran S Vasan Journal: N Engl J Med Date: 2002-10-31 Impact factor: 91.245
Authors: Andrew P Ambrosy; Adrian F Hernandez; Paul W Armstrong; Javed Butler; Allison Dunning; Justin A Ezekowitz; G Michael Felker; Stephen J Greene; Padma Kaul; John J McMurray; Marco Metra; Christopher M O'Connor; Shelby D Reed; Phillip J Schulte; Randall C Starling; W H Wilson Tang; Adriaan A Voors; Robert J Mentz Journal: Eur J Heart Fail Date: 2015-10-14 Impact factor: 15.534
Authors: Piotr Ponikowski; Stefan D Anker; Khalid F AlHabib; Martin R Cowie; Thomas L Force; Shengshou Hu; Tiny Jaarsma; Henry Krum; Vishal Rastogi; Luis E Rohde; Umesh C Samal; Hiroaki Shimokawa; Bambang Budi Siswanto; Karen Sliwa; Gerasimos Filippatos Journal: ESC Heart Fail Date: 2014-09
Authors: Andrew P Ambrosy; Gregg C Fonarow; Javed Butler; Ovidiu Chioncel; Stephen J Greene; Muthiah Vaduganathan; Savina Nodari; Carolyn S P Lam; Naoki Sato; Ami N Shah; Mihai Gheorghiade Journal: J Am Coll Cardiol Date: 2014-02-05 Impact factor: 24.094
Authors: Richard Whaddon Parsons; Danny Liew; A Munro Neville; Ralph G Audehm; Deepak Haikerwal; Peter Piazza; Kevin Lim; Andrew P Sindone Journal: BMC Public Health Date: 2020-05-11 Impact factor: 3.295